Research Literacy
How to Read ClinicalTrials.gov
The short answer
A registry listing is a snapshot, not a verdict — five fields do most of the work: status, primary completion date, whether results have been posted, the sponsor, and enrollment. BPC-157's only completed human trial (NCT02637284, 42 people, finished dosing in 2016) has sat at Unknown status for roughly a decade with no results ever filed. A 320-person Phase 2 ipamorelin trial (NCT01280344) shows the same gap despite reaching Completed status. By contrast, semaglutide's STEP 1 trial (NCT03548935, 1,961 people, sponsored by Novo Nordisk) completed on schedule and does show posted results — a useful benchmark for what a fully reported trial record looks like.
Quick answers
- What is it?
- How to read a ClinicalTrials.gov registry listing so it tells you something true.
- Why are people interested in it?
- People researching a drug or peptide often check its trial registry listing and need to know how to interpret status fields correctly.
- What has actually been studied?
- Specific registry records compared side by side, including BPC-157's only completed human trial, a 320-person ipamorelin trial, a terminated CJC-1295 trial, and the fully reported semaglutide STEP 1 trial.
- How strong is the evidence?
- This is a literacy guide rather than an efficacy claim — it uses real registry examples to show that Completed status does not mean results were ever reported, and Unknown status doesn't mean the trial failed, just that no one updated the record.
- What don't we know yet?
- Why specific trials go quiet, how common this pattern is across the peptide and hormone-therapy space, and whether an Unknown-status trial's data exists somewhere else that was just never filed to the registry.
- Where can I read the original research?
- Sources at the bottom of this page: Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157 and Phase II Double-Blind Placebo-Controlled Dose Finding Study to Evaluate Safety/Efficacy of Ipamorelin for Recovery of Gastrointestinal Function After Bowel Resection.
The short answer: ClinicalTrials.gov is a registry, not a results database — a study can sit in it for years contributing nothing but a title and a status field. Five fields do most of the interpretive work: status, primary completion date, whether results have been posted, the sponsor, and enrollment. BPC-157's only completed human trial, a 42-person Phase 1 study (NCT02637284), finished dosing volunteers in 2016 and has sat at Unknown status ever since, with no results ever filed. A 320-person Phase 2 ipamorelin trial (NCT01280344) reached the more reassuring-sounding "Completed" status in 2014 — and still has no posted results. By contrast, semaglutide's STEP 1 trial (NCT03548935), a 1,961-person Phase 3 study sponsored by Novo Nordisk, completed on schedule and does show posted results, which is what a fully reported record actually looks like.
What the research shows
The registry is a filing cabinet, not a scoreboard
ClinicalTrials.gov exists so that anyone — a researcher, a clinician, a curious member of the public — can find out that a given study was registered, what it planned to measure, and, ideally, what it found. Registration itself is largely a formality: a sponsor submits a title, a design, an intervention, and a set of planned outcomes before or shortly after the trial starts. None of that requires the trial to succeed, finish on time, or ever report anything back. That gap between "registered" and "reported" is where most of the misreading happens, and it's worth walking through with real examples rather than the field names alone.
Status: five words that mean five very different things
The "status" field is the single most load-bearing piece of information on a listing, and it takes one of several values: Recruiting, Not Yet Recruiting, Active Not Recruiting, Completed, Terminated, Withdrawn, or Unknown. Recruiting and Not Yet Recruiting mean the trial hasn't finished — there's nothing to report yet, by definition. Completed means the trial ran its planned course. Terminated and Withdrawn both mean the trial stopped early, but for different reasons — Withdrawn generally means it stopped before enrolling anyone, while Terminated means it stopped partway through, for a reason that may or may not be documented in the public record. NCT00267527, a Phase 2 trial testing CJC-1295 for HIV-associated visceral obesity, planned to enroll 120 people starting in December 2005; its status is Terminated, its completion date is listed as September 2006, and the public record available through the registry's structured fields doesn't state why it stopped. No results were ever filed.
Unknown status is its own category, and it's the one most worth understanding on sight. A trial gets marked Unknown when its listed completion date has passed but the sponsor never updated or re-verified the record afterward — the registry isn't asserting the trial failed, or that no one knows what happened internally; it's flagging that nobody has told the public registry anything since. NCT02637284, the Phase 1 BPC-157 pharmacokinetics trial run by PharmaCotherapia d.o.o. in Tijuana, is a clean example: it enrolled 42 healthy volunteers, ran from October 2015 to a completion date of March 2016, and has shown Unknown status ever since — going on a decade with no update and no results.
Completed is not the same as reported
The more instructive trap is a trial that reaches Completed status and still never reports anything. NCT01280344 tested ipamorelin, a growth hormone secretagogue, for recovery of gastrointestinal function after bowel resection surgery — a large trial by this field's standards, with 320 people enrolled across 45 locations, sponsored by Helsinn Therapeutics. It reached Completed status, with a completion date in 2014. The registry's own results-reporting field shows no results have ever been posted. A reader who checks only the status field would reasonably assume "Completed" means the story has an ending on the public record. It doesn't, in this case — the trial ran, and whatever it found was never made available through the registry.
What a fully reported trial looks like, for contrast
It's worth knowing what the alternative looks like, because it isn't rare — it's just not guaranteed. NCT03548935, the STEP 1 trial that established semaglutide's weight-loss effect, enrolled 1,961 adults across sites in more than a dozen countries, sponsored directly by Novo Nordisk. It reached Completed status on its planned timeline and shows posted results on the registry — the primary and secondary outcome data, structured and available, exactly the way the reporting system is designed to work. Large, well-resourced sponsors running pivotal trials for drugs headed toward approval are the population where this system tends to function as intended. Smaller trials, early-phase pilot studies, and sponsors without a regulatory submission riding on the outcome are where records are more likely to go quiet.
A practical reading order
Given a listing, the fields worth checking in sequence are: the status field itself; the primary completion date, compared to today's date, to see whether "in progress" claims still hold up; whether results have been posted, which on the registry is a distinct, checkable field rather than something you should infer from status; the sponsor, since that tells you who is nominally accountable for updating the record; and enrollment, comparing the number planned against the number actually reached, which can reveal a trial that fell well short of its design without ever formally being marked Terminated.
What we don't know yet
Why specific trials go quiet. The registry's structured fields do not require a sponsor to explain why a trial was terminated, or why a completed trial's results were never filed. NCT00267527's termination and NCT02637284's decade of silence are both visible in the data; the reasons behind them are not.
How common this pattern is across the peptide and hormone-therapy space specifically. This piece verified individual examples rather than a systematic count of unreported trials across an entire drug class — a bounded question a dedicated survey of the registry could answer but a single article cannot.
Whether an Unknown-status trial's data exists somewhere else. A trial can be complete internally, with a sponsor holding full data, while its public registry entry never gets updated. The registry can't distinguish "nothing happened" from "something happened and was never filed here."
Sources
- ClinicalTrials.gov. Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157. NCT02637284. Record
- ClinicalTrials.gov. Phase II Double-Blind Placebo-Controlled Dose Finding Study to Evaluate Safety/Efficacy of Ipamorelin Compared to Placebo for Recovery of Gastrointestinal Function. NCT01280344. Record
- ClinicalTrials.gov. A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study to Evaluate the Efficacy and Safety of CJC 1295 in HIV Infected Patients With HIV Associated Visceral Obesity. NCT00267527. Record
- ClinicalTrials.gov. Effect and Safety of Semaglutide 2.4 mg Once-Weekly in Subjects With Overweight or Obesity (STEP 1). NCT03548935. Record
Article records maintained via PubMed. Peptide Proof reports what studies found. It does not provide medical advice, dosing guidance, or treatment recommendations.
Sources
- Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157
- ClinicalTrials.gov · NCT02637284, 2015 · n=42
- Phase II Double-Blind Placebo-Controlled Dose Finding Study to Evaluate Safety/Efficacy of Ipamorelin for Recovery of Gastrointestinal Function After Bowel Resection
- ClinicalTrials.gov · NCT01280344, 2011 · n=320
- A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study to Evaluate the Efficacy and Safety of CJC 1295 in HIV Infected Patients With HIV Associated Visceral Obesity
- ClinicalTrials.gov · NCT00267527, 2005 · n=120
- Effect and Safety of Semaglutide 2.4 mg Once-Weekly in Subjects With Overweight or Obesity (STEP 1)
- ClinicalTrials.gov · NCT03548935, 2018 · n=1961
Get the evidence, not the hype.
New research briefs, plainly written and fully sourced. No dosing advice, ever.